

Confirmed Speakers

Confirmed speakers

DNA Methylation Inhibitors In Cancer: Recent and Future Approaches



Dr Paola B. ARIMONDO
(INSTITUT PASTEUR - CNRS, Paris, France)

Sometimes You Just Have to Break the Rules ..



Dr Yves P. AUBERSON
(NOVARTIS INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

A Yeast-based Model for Prion Disease Allowed Isolation of Specific and Competitive Inhibitors of a New Protein Chaperone Activity Borne by the Ribosome that are Active Against Other Amyloid-based Diseases



Prof. Marc BLONDEL
(INSERM, Brest, France)

JNJ-42153605: A Novel Positive Allosteric Modulator of mGluR2 for the Treatment of CNS Disorders



Dr Jose CID
(JANSSEN RESEARCH AND DEVELOPMENT, Toledo, Spain)

Accelerating Drug Discovery through High Throughput Medicinal Chemistry - Alternative Lead Finding & Optimisation Approaches Including Representative Project Examples



Dr Werngard CZECHTIZKY
(SANOFI, Frankfurt am Main, Germany)

Squalenoyl Nanomedicines as Potential Therapeutics



Dr Didier DESMAËLE
(UNIVERSITÉ PARIS SUD, Châtenay-Malabry, France)

Reduce to the Max – Probing Biology with Natural Product Fragments



Prof. Karl GADEMANN
(UNIVERSITY OF BASEL, Zürich, Switzerland)

Antagonists of the p53/hdm2 Protein-Protein Interaction - Path to the Clinic



Dr Carlos GARCIA-ECHEVERRIA
(SANOFI, Vitry sur Seine, France)

Bicyclic Peptide Antagonists Isolated From Phage Display Libraries

Confirmed Speakers



Prof. Christian HEINIS
(ECOLE POLYTECHNIQUE FÉDÉRALE DE LAUSANNE (EPFL), Lausanne, Switzerland)

Perspectives in Structure and Fragment Based Drug Discovery



Prof. Rod HUBBARD
(UNIVERSITY OF YORK / VERNALIS, York, United Kingdom)

Structure and Function of Acid-Sensing Ion Channels



Dr Stephan KELLENBERGER
(UNIVERSITÉ DE LAUSANNE, Lausanne, Switzerland)

Targeting Protein Interactions Mediated by Epigenetic Acetyl-lysine Reader Domains of the Bromodomain Family



Prof. Stefan KNAPP
(OXFORD UNIVERSITY, Oxford, United Kingdom)

Protein-binding Prodrugs and Drug Conjugates in Oncology: From Design, Applications to Combination Therapy



Prof. Felix KRATZ
(TUMOR BIOLOGY CENTER, Freiburg, Germany)

Pharmacophore-based Parallel in Silico Screening: An Interesting Concept for Efficient Activity Profiling in Drug Discovery



Prof. Thierry LANGER
(PRESTWICK CHEMICAL, Vienna, Austria)

Translating Structural-biology & Preclinical Activity of Nilotinib into Efficacy in Leukemia Patients



Dr Paul W. MANLEY
(NOVARTIS PHARMA, Basel, Switzerland)

Two Chemical/Biological Approaches to Alzheimer's Disease: Prevention and Therapy Charles Mentzer Prize Lecture



Dr Laurent MEIJER
(MANROS THERAPEUTICS, Roscoff, France)

From ApoA1 Upregulation to BET Family Bromodomain Inhibition: Unlocking the Potential of an Epigenetic Target Class

Confirmed Speakers



Dr Olivier MIRGUET
(GLAXOSMITHKLINE, Les Ulis, France)

Synthetic Carbohydrates in the Search for Tailor-made Antibacterial Vaccines: Shigellosis as a Challenge



Dr Laurence MULARD
(PASTEUR INSTITUTE, Paris, France)

Chemical space exploration via Natural Product-like compounds



Dr Jean-Yves ORTHOLAND
(EDELIRIS, Lyon, France)

Discovery of RG1678, a First in Class Glycine Reuptake Inhibitor for the Treatment of Schizophrenia



Dr Emmanuel PINARD
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

A Look at Some Innovative Chemical Aspects in Medicinal Chemistry, about Heterocycles, Microwaves, Chemical Libraries, Boronics and Garlands Paul Ehrlich Prize Lecture



Prof. Sylvain RAULT
(UNIVERSITÉ DE CAEN, Caen Cedex, France)

Combined Use of Noncovalent Mass Spectrometry and Other Biophysical Techniques in Early-stage Drug Discovery



Dr Jean-Paul RENAUD
(NOVALIX, Ostwald, France)

Sorafenib – A Signal Transduction Inhibitor for the Treatment of Liver Cancer



Dr Bernd RIEDL
(BAYER PHARMA, Wuppertal, Germany)

Progress on Allosteric Modulation of mGluR5 and mGluR4: towards New Treatment Paradigms in Parkinson's Disease



Dr Jean-Philippe ROCHER
(ADDEX THERAPEUTICS, Plan-les-Ouates, Switzerland)

Potent Antibody Drug Conjugates for Cancer Therapy: From the Lab to a Clinically Approved Drug

Confirmed Speakers



Dr Peter SENTER
(SEATTLE GENETICS, Bothell, United States)

SV2 Proteins Beyond Levetiracetam: The Discovery of the First SV2C Selective Ligands



Dr Anne VALADE
(UCB, Braine-l'Alleud, Belgium)

Matched Triplicate Design Sets in the Optimisation of a New Series of Glucokinase Activators



Prof. Mike WARING
(ASTRAZENECA, Newcastle upon Tyne, United Kingdom)